Submissions from 2016
A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use, P. Baird, S. Leung, H. Hoang, O. Babalola, C. E. Devoe, R. Wanchoo, and K. D. Jhaveri
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia, J. C. Byrd, B. Harrington, S. O'Brien, J. A. Jones, A. Schuh, S. Devereux, J. Chaves, W. G. Wierda, J. C. Barrientos, R. R. Furman, and +20 additional authors
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials, J. J. Castillo, F. Mulkey, S. Geyer, J. E. Kolitz, W. Blum, B. L. Powell, S. L. George, R. A. Larson, and R. M. Stone
Pomalidomide reverses gamma-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors, B. M. Dulmovits, A. O. Appiah-Kubi, J. Papoin, M. He, Y. Al-Abed, S. Didier, M. Gould, S. Husain-Krautter, S. A. Singh, A. Vlachos, S. L. Allen, J. M. Lipton, J. M. Liu, L. Blanc, and +7 additional authors
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies, H. Raftopoulos, A. Laadem, P. J. Hesketh, J. Goldschmidt, N. Gabrail, C. Osborne, M. Ali, M. L. Sherman, D. Wang, J. Crawford, and +3 additional authors
Chronic lymphocytic leukemia (CLL) - Then and Now, K. R. Rai and P. Jain
A Phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: A Trial of the ECOG-ACRIN Cancer Research Group (E1908), C. S. Zent, X. V. Wang, R. P. Ketterling, C. A. Hanson, E. N. Libby, J. C. Barrientos, T. G. Call, J. E. Chang, J. J. Liu, M. S. Tallman, and +5 additional authors
Submissions from 2015
Adoption of a Uniform Start Date for Internal Medicine Fellowships and Other Advanced Training: An AAIM White Paper, J. C. Barrett, R. Alweis, M. Frank, A. O'Connor, J. F. McConville, N. D. Adams, L. Arfons, S. Bernard, T. Bradley, E. A. Muchmore, and +13 additional authors
Management of Chronic Lymphocytic Leukemia in the Elderly, J. C. Barrientos
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data, S. E. Bates, R. Eisch, A. Ling, D. Rosing, M. Turner, S. Pittaluga, H. M. Prince, M. H. Kirschbaum, S. L. Allen, R. L. Piekarz, and +15 additional authors
Clinical features, and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3), B. Bhatnagar, J. S. Blachly, J. Kohlschmidt, A. K. Eisfeld, S. Volinia, D. Nicolet, A. J. Carroll, A. M. Block, J. E. Kolitz, C. D. Bloomfield, and +3 additional authors
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia, J. R. Brown, J. C. Barrientos, P. M. Barr, I. W. Flinn, J. A. Burger, A. Tran, F. Clow, D. F. James, K. Rai, S. O'Brien, and +2 additional authors
Phase II, Multicenter, Randomized Trial of CPX-351 (cytarabine: daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML, J. E. Cortes, S. L. Goldberg, E. J. Feldman, D. A. Rizzeri, D. E. Hogge, M. Larson, A. Pigneux, C. Recher, G. Schiller, J. E. Kolitz, and +3 additional authors
Management of adverse events associated with idelalisib treatment: expert panel opinion, S. E. Coutre, J. C. Barrientos, J. R. Brown, S. de Vos, R. R. Furman, M. J. Keating, D. Li, S. M. O'Brien, J. M. Pagel, A. D. Zelenetz, and +3 additional authors
Prospective contouring rounds: A novel, high-impact tool for optimizing quality assurance, B. W. Cox, A. Kapur, A. Sharma, L. Lee, B. Bloom, R. Sharma, G. Goode, and L. Potters
Acquired factor V inhibitor after exposure to topical human thrombin related to an otorhinolaryngological procedure, K. Donohoe and R. Levine
PEG-asparaginase induced severe hypertriglyceridemia, R. J. Galindo, J. Yoon, C. Devoe, and A. K. Myers
B-cell precursor acute lymphoblastic leukemia with isolated t(14;19)(q32;q13) abnormality involving the CEBPG gene, N. Haghi, J. Brody, N. Mahmood, D. Gheewala, S. L. Allen, C. Sreekantaiah, and X. Zhang
Non-Small-Cell Lung Cancer Clinicopathologic Features and Survival Outcomes in Asian Pacific Islanders Residing in the United States: A SEER Analysis, M. S. Hamid, R. Shameem, K. Gafoor, J. George, B. Mina, and K. Sullivan
Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: A phase I study in chronic lymphocytic leukemia, M. E. Kalaycio, O. G. Negrea, S. L. Allen, K. R. Rai, R. M. Abbasi, H. Horne, W. A. Wegener, and D. M. Goldenberg
Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo) Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer, I. E. Krop, T. M. Suter, C. T. Dang, L. Dirix, G. Romieu, C. Zamagni, M. L. Citron, M. Campone, N. Xu, M. Smitt, and L. Gianni
Integrating targeted drugs with taxanes and platinums: opportunities and challenges, D. Kudlowitz, E. Teplinsky, and F. Muggia
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance), J. A. Ligibel, C. T. Cirrincione, M. Liu, M. Citron, J. N. Ingle, W. Gradishar, S. Martino, W. Sikov, R. Michaelson, W. T. Barry, and +6 additional authors
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations, R. C. Lindsley, B. G. Mar, E. Mazzola, P. V. Grauman, S. Shareef, S. L. Allen, A. Pigneux, M. Wetzler, R. K. Stuart, B. L. Ebert, and +9 additional authors
Myelodysplastic syndromes spatial clusters in disease etiology and outcome, B. Liu, S. M. Kerath, M. A. Sekeres, J. P. Fryzek, C. Sreekantaiah, C. R. Mason, J. Kolitz, and E. Taioli
A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes, B. A. McCarthy, S. Yancopoulos, X. J. Yan, X. P. Wang, W. Li, M. Lesser, S. Paul, E. Boyle, C. Moreno, R. Catera, B. T. Messmer, J. E. Kolitz, S. L. Allen, K. R. Rai, N. Chiorazzi, and +5 additional authors
Introduction: moving beyond chemotherapy, F. Muggia and E. Teplinsky
Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome, B. Nazha, G. Garcia, R. Kandov, and M. Odaimi
Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue, B. R. Page, E. G. Shaw, L. Lu, D. Bryant, D. Grisell, G. J. Lesser, D. C. Monitto, M. J. Naughton, S. R. Savona, M. D. Chan, and +3 additional authors
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria, H. Raftopoulos, R. Boccia, W. Cooper, E. O'Boyle, and R. J. Gralla
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide, D. Sanford, F. Lo-Coco, M. A. Sanz, E. Di Bona, S. Coutre, J. K. Altman, M. Wetzler, S. L. Allen, F. Ravandi, H. Kantarjian, and J. E. Cortes
Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer, E. Sarafraz-Yazdi, C. Gorelick, A. R. Wagreich, G. Salame, M. Angert, C. H. Gartman, V. Gupta, W. B. Bowne, Y. C. Lee, J. Michl, and +2 additional authors
Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis, R. Sharma, A. Keyzner, J. Liu, T. Bradley, and S. L. Allen
Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes, B. Sherry, P. Jain, P. Y. Chiu, L. Leung, S. L. Allen, J. E. Kolitz, K. R. Rai, J. Barrientos, S. Liang, R. Hawtin, and N. Chiorazzi
Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia, R. M. Stone, E. Mazzola, D. Neuberg, S. L. Allen, A. Pigneux, R. K. Stuart, M. Wetzler, D. Rizzieri, H. P. Erba, B. Powell, and +12 additional authors
Primary extranodal marginal zone lymphoma of the endometrium: report of four cases and review of literature, F. C. Tahmasebi, S. Roy, J. E. Kolitz, F. Sen, J. Laser, and X. Zhang
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs, A. Tefferi, K. Rai, A. I. Schafer, C. Schiffer, M. A. Sekeres, L. L. Siu, F. M. Stewart, M. Thompson, J. M. Vose, P. H. Wiernik, and +109 additional authors
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?, E. Teplinsky and F. J. Esteva
EGFR and HER2: is there a role in ovarian cancer?, E. Teplinsky and F. Muggia
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia, E. Tiacci, J. H. Park, L. De Carolis, S. S. Chung, A. Broccoli, S. Scott, F. Zaja, S. Devlin, K. R. Rai, M. S. Tallman, and +31 additional authors
Augmenting NF-kappaB in poor-risk CLL: A general paradigm for other cancers?, D. Tuveson and K. R. Rai
Bleomycin-induced flagellate erythema in a patient with Hodgkin's lymphoma - A case report and review of literature, A. Vennepureddy, M. N. Siddique, M. Odaimi, and T. Terjanian
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results, M. L. Wang, K. A. Blum, P. Martin, A. Goy, R. Auer, B. S. Kahl, W. Jurczak, R. H. Advani, J. C. Barrientos, S. Rule, and +14 additional authors
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, W. H. Wilson, R. M. Young, R. Schmitz, Y. D. Yang, S. Pittaluga, G. Wright, C. J. Lih, P. M. Williams, J. C. Barrientos, L. M. Staudt, and +20 additional authors
Giant Cell Tumor of the Larynx Treated by Surgery and Adjuvant Denosumab: Case Report and Review of the Literature, A. E. Yancoskie, D. K. Frank, J. E. Fantasia, S. Savona, N. Eiseler, I. Reder, and L. B. Kahn
"The Great Mimicker": An Unusual Etiology of Cytopenia, Diffuse Lymphadenopathy, and Massive Splenomegaly, M. Zaarour, C. Weerasinghe, E. Moussaly, S. Hussein, and J. P. Atallah
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer, M. Zaarour, C. Weerasinghe, B. Nazha, S. Hassan, and J. P. Atallah
Submissions from 2014
Prognostic significance of isolated t(8:14) in chronic lymphocytic leukemia, J. R. Asirvatham, J. Brody, R. Vora, J. E. Kolitz, S. Z. Fields, C. Sreekantaiah, and X. M. Zhang
More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review, F. Badulescu, A. Badulescu, D. Paul, C. F. Popescu, and C. Florescu
Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8, H. Becker, K. Maharry, K. Mrozek, S. Volinia, A. K. Eisfeld, M. D. Radmacher, J. Kohlschmidt, K. H. Metzeler, J. E. Kolitz, C. D. Bloomfield, and +14 additional authors
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103), J. H. Beumer, K. Owzar, L. D. Lewis, C. Jiang, J. L. Holleran, S. M. Christner, W. Blum, S. Devine, J. E. Kolitz, M. J. Egorin, and +5 additional authors
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia, J. C. Byrd, J. R. Brown, S. O'Brien, J. C. Barrientos, N. E. Kay, N. M. Reddy, S. Coutre, C. S. Tam, S. P. Mulligan, P. Hillmen, and +25 additional authors
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia, R. Claus, D. M. Lucas, A. S. Ruppert, K. E. Williams, D. Weng, K. Patterson, M. Zucknick, J. C. Barrientos, K. R. Rai, J. C. Byrd, and +13 additional authors
The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide, C. E. Devoe, J. Y. Li, and A. M. Demopoulos
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia, R. R. Furman, J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel, P. Hillmen, J. C. Barrientos, A. D. Zelenetz, T. J. Kipps, S. M. O'Brien, and +17 additional authors
Expression and prognostic impact of lncRNAs in acute myeloid leukemia, R. Garzon, S. Volinia, D. Papaioannou, D. Nicolet, J. Kohlschmidt, P. S. Yan, K. Mrozek, D. Bucci, J. E. Kolitz, C. D. Bloomfield, and +15 additional authors
Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia, J. Houldsworth, A. Guttapalli, V. Thodima, X. J. Yan, G. Mendiratta, T. Zielonka, G. Nanjangud, K. Rai, N. Chiorazzi, R. S. K. Chaganti, and +4 additional authors
IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria, K. K. Hwang, A. M. Trama, D. M. Kozink, S. L. Allen, K. R. Rai, R. Catera, X. J. Yan, C. C. Chu, N. Chiorazzi, B. F. Haynes, and +12 additional authors
Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium, D. F. James, L. Werner, J. R. Brown, W. G. Wierda, J. C. Barrientos, J. E. Castro, A. Greaves, A. J. Johnson, K. R. Rai, T. J. Kipps, and +2 additional authors
Recombinant Interleukin-2 in Patients Aged Younger Than 60 Years With Acute Myeloid Leukemia in First Complete Remission, J. E. Kolitz, S. L. George, D. M. Benson, K. Maharry, G. Marcucci, R. Vij, B. L. Powell, S. L. Allen, D. J. DeAngelo, Oncology Alliance Clinical Trials, and +8 additional authors
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML, J. E. Lancet, J. E. Cortes, D. E. Hogge, M. S. Tallman, T. J. Kovacsovics, L. E. Damon, R. Komrokji, S. R. Solomon, J. E. Kolitz, E. J. Feldman, and +3 additional authors
Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score, G. Marcucci, P. Yan, K. Maharry, D. Frankhouser, D. Nicolet, K. H. Metzeler, J. Kohlschmidt, K. Mrozek, J. E. Kolitz, C. D. Bloomfield, and +21 additional authors
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia, C. Niederwieser, J. Kohlschmidt, S. Volinia, S. P. Whitman, K. H. Metzeler, A. K. Eisfeld, K. Maharry, P. Yan, J. E. Kolitz, C. D. Bloomfield, and +17 additional authors
Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus, K. Patel, R. Kabir, S. Ahmad, and S. L. Allen
Prolonged survival in metastatic colorectal cancer following chemotherapy, D. Paul, M. Gold, and N. Nouraddin
Movement toward Optimization of CLL Therapy, K. R. Rai and J. C. Barrientos
Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine, R. Wanchoo, S. Khan, J. E. Kolitz, and K. D. Jhaveri
GAS6 expression identifies high-risk adult AML patients: potential implications for therapy, S. P. Whitman, J. Kohlschmidt, K. Maharry, S. Volinia, K. Mrozek, D. Nicolet, S. Schwind, H. Becker, J. E. Kolitz, C. D. Bloomfield, and +11 additional authors
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, J. A. Woyach, R. R. Furman, T. M. Liu, H. G. Ozer, M. Zapatka, A. S. Ruppert, L. Xue, D. H. H. Li, J. C. Barrientos, J. C. Byrd, and +15 additional authors